FDA Approves Once-Weekly Product for Hemophilia A

The new product, efanesoctocog alfa (Altuviiio), is a long-acting factor VIII replacement that needs to be given only once weekly.
FDA Approvals

source https://www.medscape.com/viewarticle/988712?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost